Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
August 26th, 2025
Pulmonary vein stenosis (PVS) is a life-threatening complication of fibrosing mediastinitis (FM), with a poor prognosis if not properly treated. Currently, catheter-based endovascular angioplasty is a promising therapeutic strategy for FM-associated PVS. This protocol primarily outlines a stepwise approach to the transcatheter procedure for FM-associated PVS.
This study primarily focused on pulmonary vein stenosis caused by fibrosing mediastinitis, and mainly presents the interventional treatment steps for pulmonary vein stenosis for a beginner's reference and learning. The latest research identifies the pulmonary vein diameter and the corresponding pulmonary artery stenosis as predictors of restenosis. Our cohort study confirms re-stenting is more effective than balloon dilation for restenosis.
I think drug-eluting balloons could be an effective solution for restenosis and prospective studies are need to confirm this. Pulmonary vein intervention requires atrial septum puncture, and in these patients, the left atrium is often smaller. Additionally, selective pulmonary vein angiography is performed in retrograde flow, increasing difficulty.
I proposed the dural triple sign and Yunshan's sign for fibrosing mediastinitis screening, along with a clinical classification and a stenosis scoring system for preoperative assessments. To begin, assist a patient in lying down on their back. Record the electrocardiogram, heart rate, peripheral oxygen saturation, and blood pressure.
Next, connect 500 milliliters of normal saline to the peripheral venous access line. Flush all the catheters with heparinized saline to prevent thromboembolic complications. To establish femoral vein access, first, insert an eight French catheter sheath into the right femoral vein on the sterilized right groin.
Insert a 0.035 inch guidewire. Deliver the guiding catheter to the right superior pulmonary artery via the guidewire. Then, withdraw the guidewire.
Perform selective right superior pulmonary artery angiography to establish the location of the left atrium in the 45 degree right anterior oblique view. For transseptal catheterization, insert a 0.032 inch J-tip guidewire into the superior vena cava. Then, remove the eight French catheter sheath.
Advance the transseptal guiding sheath dilator assembly into the superior vena cava over the J-tip guidewire under anterior posterior fluoroscopy. Remove the guidewire from the dilator. Advance the transseptal needle into the dilator.
Position the transseptal needle and stylet assembly until the stylet is positioned just proximal to the dilator tip inside the sheath. Then, remove the stylet. Next, retract the entire assembly and adjust the pointer flange so that the needle is positioned perpendicular to the fossa ovalis in the anterior-posterior view.
Use fluoroscopy to verify that the needle tip is within the dilator. Visualize and identify anatomic landmarks in the 45 degree right anterior oblique view. Then, extend the needle to full engagement within the sheath dilator assembly.
Advance it across the interatrial septum. Maintain a fixed needle position within the left atrium. Then, advance the sheath dilator assembly fully over the needle into the left atrial cavity.
Remove the transseptal needle from the dilator. Next, insert a 0.035 inch guidewire and advance it into the left superior pulmonary vein. Advance the sheath fully into the left atrial cavity over the dilator.
Then, withdraw the dilator. Now, insert the guiding catheter, advance it into the left atrium over the guidewire and withdraw the guidewire. Measure the left atrial pressure via the guiding catheter.
To begin, monitor the vitals of a patient with fibrosing mediastinitis-associated pulmonary vein stenosis. Insert a 0.014 inch Runthrough guidewire into the distal left superior pulmonary vein. Gently pass the guiding catheter over the wire.
Position its tip at the distal part of the stenosis. Perform selective pulmonary venography to evaluate the lesion's location, severity of stenosis, and grade of pulmonary vein flow. Record pressure measurements of the distal part of the stenosis.
Retract the JR guiding catheter to the proximal part. Then, measure the proximal pressure and calculate the pressure gradient between the two sides of the lesion. For balloon angioplasty and stent implantation, first, choose an appropriately sized balloon based on computed tomography pulmonary angiography and pulmonary venography data.
Perform gradual dilation at the most stenotic part of the vein. Then, remove the balloon delivery catheter and repeat angiography. Retract the guiding catheter.
Advance an appropriately sized stent over the guidewire into the stenotic vein. Then, perform the stenting procedure. Finally, remove the guidewire and transseptal sheath.
Press the puncture site manually and apply an elastic bandage to prevent bleeding. The catheter-based endovascular angioplasty resulted in a significant reduction in the pressure gradient across the stenotic lesions.
View the full transcript and gain access to thousands of scientific videos
Overview
Pulmonary vein stenosis (PVS) is a serious complication of fibrosing mediastinitis (FM) that requires effective treatment strategies. This study outlines a transcatheter approach to manage FM-associated PVS, emphasizing the importance of intervention techniques.
Key Study Components
Area of Science
- Interventional cardiology
- Pulmonary medicine
- Vascular surgery
Background
- Pulmonary vein stenosis can lead to severe health complications if untreated.
- Fibrosing mediastinitis is a condition that can cause PVS.
- Current treatment options include catheter-based endovascular angioplasty.
- Understanding predictors of restenosis is crucial for improving outcomes.
Purpose of Study
- To provide a stepwise approach for the transcatheter procedure for FM-associated PVS.
- To evaluate the effectiveness of re-stenting compared to balloon dilation.
- To explore the potential of drug-eluting balloons for preventing restenosis.
Methods Used
- Conducted a cohort study to assess treatment outcomes.
- Performed selective pulmonary vein angiography.
- Utilized atrial septum puncture for intervention.
- Analyzed predictors of restenosis based on pulmonary vein diameter.
Main Results
- Re-stenting was found to be more effective than balloon dilation for restenosis.
- Identified pulmonary vein diameter and pulmonary artery stenosis as predictors of restenosis.
- Drug-eluting balloons showed promise as a potential solution.
- Intervention techniques presented challenges due to anatomical variations.
Conclusions
- Transcatheter approaches can effectively manage FM-associated PVS.
- Further studies are needed to validate the use of drug-eluting balloons.
- Understanding anatomical challenges is essential for successful interventions.
Frequently Asked Questions
Executive Industry Relevance
Catheter-based endovascular angioplasty for fibrosing mediastinitis-associated pulmonary vein stenosis addresses a critical need for precise intervention in rare, high-risk vascular complications. The approach enables quantitative assessment of lesion severity and procedural efficacy, supporting predictive confidence in restenosis risk and informing portfolio decisions for device and interventional innovation. Integration of anatomical scoring and hemodynamic monitoring enhances mechanistic de-risking and cross-functional R&D alignment.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables quantitative hypothesis testing of restenosis predictors such as vein diameter and artery stenosis.
- Supports mechanistic de-risking by correlating anatomical features with intervention outcomes.
- Facilitates functional validation of device-based therapeutic strategies in complex vascular settings.
Screening & Assay Development
- Establishes reproducible measurement of pressure gradients and flow for standardized assessment.
- Provides validated imaging and scoring systems for pre-intervention stratification.
- Enables consistent evaluation of device performance across patient cohorts.
Translational & Preclinical Research
- Aligns anatomical and hemodynamic biomarkers with clinical endpoints for translational continuity.
- Supports risk-adjusted advancement of novel devices such as drug-eluting balloons.
- Facilitates preclinical modeling of intervention efficacy and restenosis mechanisms.
Pipeline & Workflow Integration
This method bridges early discovery of restenosis mechanisms with device screening and translational validation, supporting iterative optimization from anatomical scoring to clinical intervention.
- Discovery Biology: Quantifies lesion characteristics and correlates with restenosis risk for hypothesis-driven device development.
- Screening: Standardizes pressure and imaging readouts for reproducible device evaluation.
- Analytics: Provides quantitative dependent variable measurements for cross-condition comparison.
- Translational Research: Aligns anatomical and hemodynamic data with clinical outcomes for preclinical-to-clinical continuity.
- Enterprise Reuse: Offers a reusable workflow for evaluating vascular interventions in rare disease contexts.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in restenosis risk and device efficacy.
- Operational Value: Delivers standardized, reproducible measurements for cross-study comparability.
- Strategic Value: Informs go/no-go decisions for device advancement and clinical trial design.
- Portfolio Impact: Enables risk-adjusted prioritization of interventional technologies targeting rare vascular complications.
Implementation Considerations
- Requires expertise in interventional cardiology and advanced imaging interpretation.
- Demands access to fluoroscopy, angiography, and hemodynamic monitoring infrastructure.
- Necessitates cross-team standardization of scoring and measurement protocols.
- Adaptation may be needed for anatomical variations and rare disease presentations.
- Potential limitations include procedural complexity and need for prospective validation of novel devices.
